Insider information pursuant to Article 17 MAR (Ad hoc announcement)

NOT FOR PUBLICATION OR DISTRIBUTION, WHETHER DIRECTLY OR INDIRECTLY, WITHIN OR TO THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA OR JAPAN, OR WITHIN OR TO ANY OTHER JURISDICTION IN WHICH SUCH PUBLICATION OR DISTRIBUTION WOULD BE PROHIBITED. FURTHER RESTRICTIONS APPLY.

SynBiotic SE: Majority takeover of hemp industry pioneer Daniel Kruse's group of companies as part of a capital increase in kind

Munich, November 30, 2021 - Synbiotic SE today concluded a contribution agreement for the acquisition of 50.1% of the shares of Hanf Farm GmbH, Hemp Factory GmbH, Hempro International GmbH and MH medical hemp GmbH. The shares will be contributed to the company as part of a capital increase in kind. Synbiotic SE will resolve a capital increase in kind of €450,900 by issuing 450,900 new shares. SynBiotic SE is also making a payment of €2 million into the companies' capital reserve. The combined contributed shares are valued at €11.27 million. SynBiotic SE is hence raising its sales forecast for 2021 to €15 million (pro forma consolidated).

EIHA President Daniel Kruse and industry pioneer Rafael Dulon bring a combined half a century of cannabis expertise to SynBiotic SE. With the four companies Hanf Farm GmbH (largest organic hemp cultivation firm in Europe), Hempro International GmbH (largest hemp food distributor in Central Europe, with an international supplier and customer network, and profitable own brands), Hemp Factory GmbH (largest hemp food production in Central Europe) and MH medical hemp GmbH (CBD expert and wholesaler with THC BtM approval), SynBiotic SE's portfolio is being enriched by important infrastructures and profitable brands.

About SynBiotic SE

SynBiotic SE is the largest listed group in Europe in the hemp and cannabis sector and pursues an EU-focused buy & build investment strategy. The group of companies covers the entire supply chain from cultivation to production to retail - from field to shelf. One of the company's core businesses is the research & development, production and marketing of cannabinoid- and terpene-based solutions to major societal problems such as pain, sleep and anxiety. In doing so, SynBiotic SE is active not only in the dietary supplement and cosmetics markets, but also in the medical and, in the future, recreational cannabis sector.

Further information can be found at https://www.synbiotic.com

Investor relations
Lars Müller
ir@synbiotic.com

Important information
This announcement is for informational purposes only and does not constitute an offer to buy, sell, exchange or transfer securities or the solicitation of an offer to buy securities of SynBiotic SE in the United States of America or any other jurisdiction. The SynBiotic SE securities referred to herein have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the "Securities Act") and may not be offered or sold in the United States of America absent an exemption from registration under the Securities Act. Neither SynBiotic SE nor any other party to the transaction described herein intends to register any securities described herein under the Securities Act or with any securities regulatory authority of any state or other jurisdiction in the United States of America in connection with this announcement. The securities may not be offered in any jurisdiction in circumstances that require the preparation or registration of a prospectus or offer documents relating to the securities in that jurisdiction.

Subject to certain exemptions under the Securities Act, the securities referred to in this announcement may not be offered or sold in Australia, Canada or Japan, or to or for the account of any person resident or living in Australia, Canada or Japan.

This release contains forward-looking statements that are subject to certain risks and uncertainties. Future results may differ considerably from those currently anticipated, due to various risk factors and contingencies such as changes in business, economic and competitive conditions, exchange rate fluctuations, uncertainties regarding litigation or investigative proceedings, and the availability of financial resources. SynBiotic SE assumes no responsibility to update the forward-looking statements contained in this release.